Quantification of Total HIV1-DNA in Peripheral Blood Mononuclear Cells

  • Christine Rouzioux
  • Adeline Mélard
  • Véronique Avéttand-Fénoël
Part of the Methods in Molecular Biology book series (MIMB, volume 1087)


HIV reservoir measurement in patients is one of the challenges at the time of testing new treatment approaches aiming at eradicating HIV infection. HIV reservoirs are complex and disseminated in a large number of organs and lymphoid tissues. We chose to quantify total cell-associated HIV-DNA in PBMC as a marker of HIV reservoirs and described the method we developed. The marker was used in large cohort studies at different stages of HIV disease and in therapeutical trials. Our results show how informative is this marker, as well as that plasma HIV-RNA and CD4 T cell count are representative of each patient when measured in blood. Such a series of results might help to adapt simplification or structured interruption strategies, design new clinical trials targeting HIV reservoirs, and select populations that could benefit of such new treatments.

Key words

HIV-DNA Quantification Real-time PCR Reservoirs 



Our work is supported by grants from the ANRS (Agence Nationale de Recherches sur le Sida et les Hépatites virales) and the Paris Descartes University. A. M is supported by the ANRS.


  1. 1.
    Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel MR, Ghattas G, Brenchley JM, Schacker TW, Hill BJ, Douek DC, Routy JP, Haddad EK, Sékaly RP (2009) HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 15:893–900PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Koelsch KK, Liu L, Haubrich R, May S, Havlir D, Gunthard HF, Ignacio CC, Campos-Soto P, Little SJ, Shafer R, Robbins GK, D’Aquila RT, Kawano Y, Young K, Dao P, Spina CA, Richman DD, Wong JK (2008) Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis 197:411–419CrossRefPubMedGoogle Scholar
  3. 3.
    O’Doherty U, Swiggard WJ, Jeyakumar D, McGain D, Malim MH (2002) A sensitive, quantitative assay for human immunodeficiency virus type 1 integration. J Virol 76:10942–10950PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Lewin S, Rouzioux C (2011) HIV cure and eradication: how will we get from the laboratory to effective clinical trials? AIDS 25(7):885–897CrossRefPubMedGoogle Scholar
  5. 5.
    Avettand-Fenoel V, Chaix ML, Blanche S, Burgard M, Floch C, Toure K, Allemon MC, Warszawski J, Rouzioux C (2009) LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01). J Med Virol 81:217–223CrossRefPubMedGoogle Scholar
  6. 6.
    Rouzioux C, Hubert JB, Burgard M, Deveau C, Goujard C, Bary M, Sereni D, Viard JP, Delfraissy JF, Meyer L (2005) Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis 192:46–55CrossRefPubMedGoogle Scholar
  7. 7.
    Avettand-Fenoel V, Boufassa F, Galimand J, Meyer L, Rouzioux C (2008) HIV-1 DNA for the measurement of the HIV reservoir is predictive of disease progression in seroconverters whatever the mode of result expression is. J Clin Virol 42:399–404CrossRefPubMedGoogle Scholar
  8. 8.
    Goujard C, Bonarek M, Meyer L, Bonnet F, Chaix ML, Deveau C, Sinet M, Galimand J, Delfraissy JF, Venet A, Rouzioux C, Morlat P (2006) CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis 42:709–715CrossRefPubMedGoogle Scholar
  9. 9.
    Coffie PA, Ekouevi DK, Chaix ML, Tonwe-Gold B, Clarisse AB, Becquet R, Viho I, N’Dri-Yoman T, Leroy V, Abrams EJ, Rouzioux C, Dabis F (2008) Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003–2006. Clin Infect Dis 46:611–621CrossRefPubMedGoogle Scholar
  10. 10.
    Ghosn J, Deveau C, Chaix ML, Goujard C, Galimand J, Zitoun Y, Allegre T, Delfraissy JF, Meyer L, Rouzioux C (2010) Despite being highly diverse, immunovirological status strongly correlates with clinical symptoms during primary HIV-1 infection: a cross-sectional study based on 674 patients enrolled in the ANRS CO 06 PRIMO cohort. J Antimicrob Chemother 65:741–748CrossRefPubMedGoogle Scholar
  11. 11.
    Avettand-Fenoel V, Bouteloup V, Melard A, Fagard C, Chaix ML, Leclercq P, Chene G, Viard JP, Rouzioux C (2010) Higher HIV-1 DNA associated with lower gains in CD4 cell count among patients with advanced therapeutic failure receiving optimized treatment (ANRS 123–ETOILE). J Antimicrob Chemother 65(10):2212–2214CrossRefPubMedGoogle Scholar
  12. 12.
    Martinez V, Costagliola D, Bonduelle O, N’Go-Giang-Huong N, Schnuriger A, Theodorou I, Clauvel JP, Sicard D, Agut H, Debre P, Rouzioux C, Autran B (2005) Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. J Infect Dis 191:2053–2063CrossRefPubMedGoogle Scholar
  13. 13.
    Lambotte O, Boufassa F, Madec Y, Nguyen A, Goujard C, Meyer L, Rouzioux C, Venet A, Delfraissy JF (2005) HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis 41:1053–1056CrossRefPubMedGoogle Scholar
  14. 14.
    Dalmasso C, Carpentier W, Meyer L, Rouzioux C, Goujard C, Chaix ML, Lambotte O, Avettand-Fenoel V, Le Clerc S, de Senneville LD, Deveau C, Boufassa F, Debre P, Delfraissy JF, Broet P, Theodorou I (2008) Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. PLoS One 3:e3907PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Viard JP, Burgard M, Hubert JB, Aaron L, Rabian C, Pertuiset N, Lourenco M, Rothschild C, Rouzioux C (2004) Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS 18:45–49CrossRefPubMedGoogle Scholar
  16. 16.
    Chun TW, Justement JS, Moir S, Hallahan CW, Maenza J, Mullins JI, Collier AC, Corey L, Fauci AS (2007) Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis 195:1762–1764CrossRefPubMedGoogle Scholar
  17. 17.
    Ngo-Giang-Huong N, Deveau C, Da Silva I, Pellegrin I, Venet A, Harzic M, Sinet M, Delfraissy JF, Meyer L, Goujard C, Rouzioux C (2001) Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy. AIDS 15:665–673CrossRefPubMedGoogle Scholar
  18. 18.
    Chun TW, Justement JS, Murray D, Hallahan CW, Maenza J, Collier AC, Sheth PM, Kaul R, Ostrowski M, Moir S, Kovacs C, Fauci AS (2010) Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS 24(18):2803–2808PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Piketty C, Weiss L, Assoumou L, Burgard M, Melard A, Ragnaud JM, Bentata M, Girard PM, Rouzioux C, Costagliola D (2010) A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir. J Med Virol 82(11):1819–1828CrossRefPubMedGoogle Scholar
  20. 20.
    Hocqueloux L, Prazuck T, Avettand-Fenoel V, Lafeuillade A, Cardon B, Viard JP, Rouzioux C (2010) Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS 24:1598–1601CrossRefPubMedGoogle Scholar
  21. 21.
    Graf EH, Mexas AM, Yu JJ, Shaheen F, Liszewski MK, Di Mascio M, Migueles SA, Connors M, O’Doherty U (2011) Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART. PLoS Pathog 7(2):e1001300PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Avettand-Fenoel V, Descours B, Blanc C, Samri A, Mélard A, Supervie V, Theodorou I, Carcelain G, Rouzioux C, Autran B, the ALT ANRS CO15 Study Group (2012) Immune responses driven by protective HLA alleles from LTNPs are associated with low HIV reservoir in central memory CD4 T cells. Clin Infect Dis 54(10):1495–1503CrossRefPubMedGoogle Scholar
  23. 23.
    Reuse S, Calao M, Kabeya K, Guiguen A, Gatot JS, Quivy V, Vanhulle C, Lamine A, Vaira D, Demonte D, Martinelli V, Veithen E, Cherrier T, Avettand-Fenoel V, Poutrel S, Piette J, de Launoit Y, Moutschen M, Burny A, Rouzioux C, De Wit S, Herbein G, Rohr O, Collette Y, Lambotte O, Clumeck N, Van Lint C (2009) Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One 4:e6093PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Trono D, Van Lint C, Rouzioux C, Verdin E, Barre-Sinoussi F, Chun TW, Chomont N (2010) HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 329:174–180CrossRefPubMedGoogle Scholar
  25. 25.
    Rouet F, Chaix ML, Nerrienet E, Ngo-Giang-Huong N, Plantier JC, Burgard M, Peeters M, Damond F, Koumavi ED, Msellati P, Ferradini L, Rukobo S, Marechal V, Schvachsa N, Wakrim L, Rafalimanana C, Rakotoambinina B, Viard JP, Seigneurin JM, Rouzioux C (2007) Impact of HIV-1 genetic diversity on plasma HIV-1 RNA quantification: usefulness of the Agence Nationale de Recherches sur le SIDA. Second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test. J Acquir Immune Defic Syndr 45:380–388CrossRefPubMedGoogle Scholar
  26. 26.
    Levy Y, Sereti I, Tambussi G, Routy JP, Lelievre JD, Delfraissy JF, Molina JM, Fischl M, Rodriguez B, Rouzioux C, Avettand-Fenoel V, Croughs T, Beq S, Morre M, Poulin JF, Sekaly RP, Thiebaut R, Lederman MM (2012) Effects of recombinant human interleukin 7 on T cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomised study, placebo-controlled, multicenter study. Clin Infect Dis 55:291–300PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2014

Authors and Affiliations

  • Christine Rouzioux
    • 1
    • 2
  • Adeline Mélard
    • 1
    • 3
  • Véronique Avéttand-Fénoël
    • 1
    • 4
  1. 1.Laboratoire de VirologieHôpital NeckerParisFrance
  2. 2.EA 3620, Paris Descartes UniversityParisFrance
  3. 3.EA 3620, Université Paris DescartesSorbonne Paris-CitéFrance
  4. 4.EA 3620 Université Paris DescartesSorbonne Paris-CitéFrance

Personalised recommendations